[Effect of Chuanbei Autumn Pear Cream]_action_benefit

[Effect of Chuanbei Autumn Pear Cream]_action_benefit

Chuanbei Autumn Pear Cream is a relatively common medicinal lotion, which is generally used to treat wind-heat cough. It can be used to relieve lung cough and relieve phlegm, etc. It is very effective for the conditioning of respiratory diseases, but not all cold coughs areIt can be done with Chuanbei Autumn Pear Cream.

Autumn pear cream is suitable for most foods, but it is not suitable for female friends with cold constitution, and it is not allowed to put in dry stool.

The efficacy and role of Qiuli cream Qiuli cream moisturizes the lungs and relieves cough, and stimulates the throat.

It is used for coughing and wheezing of yin deficiency and lung heat, thick sputum, stuffy chest, and dry mouth, dry throat, and irritability.

It is especially good for those who have chronic lung cough and Yin.

Autumn pear cream is mainly made of autumn pear (namely, pears or pears produced in autumn), and other medicines for cough, Shengjin, and lungs (such as chrysanthemum, fat sea, Chuanbei, Ophiopogon, Poria, Fritillaria, honeyEtc.) The ointment made from processing began in the Tang Dynasty and evolved from the “Qiu Pear Honey” contained in the book “The Herbal Medicine”.

Qiuli Pear Cream is fragrant, sweet and delicious. It is often used clinically to treat the thirst of lung heat caused by hot dry wounds, and it is dry and stuffy.

Autumn pear cream is a honey juice made from pears. Usually it looks dark in appearance, and it will be sweet and sweet when eaten alone.

Therefore, when eating autumn pear cream, you should add water to it. About 2 tablespoons of autumn pear cream are enough for one cup of water.

As we all know, pears are cool fruits, so QiuLi cream also has some health benefits of pears. Drinking it can clear the fire and moisturize the lungs. It can alleviate lung cough and dry throat.

It is more suitable for all kinds of people, as long as they are replaced with boiling water when drinking.

Autumn pear cream is suitable for anyone to drink Autumn pear cream is suitable for everyone.

Qiuli pear cream is a medicated diet drink made from the compatibility of Qiuli and expectorant Chinese medicine. The “Qiuli Honey Cream” contained in “The Herbal Medicine” is a historical record, and it is said that it began in the Tang Dynasty.

It is said that Tang Wuzong Li Yan was sick, his mouth was dry all day long, his heart was hot and short of breath, and he had no effect after taking hundreds of drugs.Honey and honey paste made with various Chinese herbal medicines cured the emperor’s illness. From then on, the priest’s recipe became a palace secret recipe until the Qing Dynasty flowed into the people.

The climate is dry in autumn and winter, and many people often have cough and uncomfortable throat.

Therefore, putting a bottle of autumn pear cream on the desk has become a habit of too many people.

But autumn pear cream is not suitable for everyone, let alone drink.

Because the main raw material of Qiuli Pear Cream is cold, and the medicines for nourishing yin and Shengjin used in Qiuli Pear Cream are also cold, so those with weak spleen and stomach, cold hands and feet, and having diarrhea should not eat QiuliIn order to prevent the symptoms of deficiency colds from getting worse, it is easier to have diarrhea, even to get angry, and people with dry stools should not drink as drinks.

Some people think that the thicker the Qiuli cream, the better, and the best way to overcome it is the fact that Qiuli cream has a lot of sugar and high osmotic pressure. Direct replacement will irritate the mouth and throat mucosa.

The correct method is to take one or two spoons and hydrate them with warm water.

How to make autumn pear cream Ingredients: pear, sugar, ginger ginger Production steps: 1. Wash and peel the autumn pear, wipe out the pear and pear juice with a wiper; 2. Put the pear and pear juice in a casserole, add rock sugar3. Add old ginger shreds; 4. Add Luo Hanguo with smashed petals; 5. Cook under low heat and simmer for 30 minutes; 6. Pour out gauze or sieve to filter out pear syrup, ginger shreds and Luo Han Guo.7, the filtered juice is poured back into the pot, open the mouth and continue to boil over low heat; 8, cook until the juice in the pot begins to thicken, continue to stir with a wooden shovel until the juice becomes thick and thick, stickyThe feeling of sticking can turn off the fire; 9. Leave the fire to dry and warm, add honey and stir well, and store in a sealed container.

When drinking, take a spoonful of warm water and cash in immediately.

[Can rambutan seeds be eaten]_Rambutan seeds_Can you eat_Is it edible

銆 愮 儿 姣 涗 涗 Abdomen 勭 勭 Benzene mutually surpassed 动 銆 慱 绾 ㈡ 璆 Gui benzene
The whole world is a good place to go, and you ca n’t walk away from the bag. You can walk through the bag and walk around. You will be able to press the button to kill each other. You will be able to talk to each other.You can use it to check the status of each other. Umbrellas, readings, readings, readings, readings, readings, readings, readings, readings, readings, etc.Songs and songs?涓€銆佺孩姣涗腹鐨勭苯鍙互鍚冨悧锛?It ‘s a matter of fact that it ‘s a good idea to take care of your fistula, and you will be able to see how it works, if you want to read it, you will be able to see how it works.浜屻€佺孩姣涗腹鐨勬纭悆娉?绾㈡瘺涓瑰張鍚嶆瘺鑽旀灊锛岀幇浠h惀鍏诲鐮旂┒鍙戠幇瀹冨惈鏈変赴瀵岀殑閽欒川銆佺7銆佺淮浠栧懡C銆傝€屼粠涓尰鐨勮搴︽潵鐪嬶紝绾㈡瘺涓规€у懗鐢樻俯锛屾灉鑲夌敇棣欑敎缇庡帤鑰屽姹侊紝闀挎湡椋熺敤鍙敓娲ュ紑鑳冦€佹鼎鑲ゅ吇棰溿€佹竻鐑В姣掋€佸寮哄厤鐤姏銆傚彲鏄孩姣涗腹鏋滃疄闀挎弧杞埡锛岃鎬庝箞鍚冨憿锛?銆侀矞椋熺孩姣涗腹鍙堝彨姣涜崝鏋濓紝鍥犱负澶栧舰灏卞儚闀挎瘺鐨勮崝鏋濄€傚畠鐨勫悆娉曞拰鑽旀灊涔熷緢鍍忥紝鍦ㄥ悆绾㈡瘺涓圭殑鏃跺€欙紝鍙鎷ㄥ紑鏌旇蒋鐨勬瘺鍒鸿交杞讳竴鎸わ紝鐧借壊閫忔槑鐨勬灉鑲夊氨闇插嚭鏉ヤ簡锛屼絾鏄悆绾㈡瘺涓硅鐢ㄧ墮鎱㈡參杞昏交鍦颁竴灞備竴灞傚挰锛屼笉鍙互蹇冩€ュぇ鍔涳紝鍚﹀垯寰堝鏄撳氨浼氭牳鏁h啘纰庯紝鑶滆倝鐩歌繛浜嗐€?銆佽尪楗妸绾㈡瘺涓规灉澹虫礂鍑€鍔犳按鐓庣叜褰撹尪楗紝鍙敼鍠勫彛鍥㈢値涓庤吂娉汇€傜孩姣涗腹妞You can use it as a guide, and you can click on it. You will be able to use it as a guide.鑸屽ご鐐庣棁鍏锋湁鏄捐憲鐨勫姛鏁堛€?銆佸埗铚滈ク銆佹灉閰便€佹灉鍐诲拰閰块厭銆?涓夈€佺孩姣涗腹鐨勯鐢ㄥ鐞嗘柟娉?1.Do you have a fistula or a fistula? Do you have a fistula? Do you have a fistula? Do you have a fistula?.绾㈡瘺涓硅鎹忓紑涓€灏忓洍銆?.灏嗗3鍓ュ紑锛岄湶鍑烘灉鑲夛紝鍚冧簡鏋滆倝锛岃寰楀悙鏍搞€?

[Fried Job’s Tears]_Chicken Head Rice_Efficacy

銆 愮 倰 咖 忕 忕 鑺 “疄 銆 慱 楦” ご 绫 砡 锷 癸 晥
寰堝浜鸿韩涓婂嚭鐜颁竴浜涚毊鑲ょ姸鍐碉紝鍏跺疄澶氬崐閮芥槸鐢变簬浣撳唴婀挎皵杩囧閫犳垚鐨勶紝鎵€浠ヨ繖鏃跺€欏氨闇€瑕佸幓闄や綋鍐呯殑婀挎皵銆傝€屼娇鐢ㄨ枏绫虫潵绁涢櫎婀挎皵锛屾槸寰堝浜洪兘鍦ㄨ繘琛岀殑涓€绉嶅緢濂界殑鏂规硶銆傚ぇ瀹跺湪鏃ュ父鐢熸椿涓拱鍥炴潵鐨勮枏绫抽兘鏄敓鐨勶紝鎵€浠ユ兂瑕佸I ‘m going to go back and forth, I ‘m going to go back and forth, I ‘m going to go back and forth, I ‘m going to press it, I ‘m going to press it, I ‘m going to do it.€璧风倰鍛紵1銆佸埗浣滄柟娉曪細1銆佺叜鍓嶅厛灏嗙孩璞嗐€佽枏绫炽€佽姟瀹炴竻娲楀共鍑€娴告场8涓 灠 灏 夔 椠 惠 ヤ 笂 Adopted  餉 愭 枡 鞡 歌 歌 frosty village village real estate?鈙  皢 绾 ㈣ 霢 ㄨ 眴 軴 嗘 満 満 Ga 撶 (镦  紑 : 屽 咢 ㄤ 簬 镦  Actually, it’s awkward?2銆佹妸娴告场濂界殑鏉愭枡鏀惧叆楂樺帇閿咃紝鍔犲叆800姣崌鐨勬竻姘淬€?銆佺敤鐓茬播妯″紡锛岄€夋嫨鈥滄祿閮佲€濆彛鎰燂紝澶ф鍗婁釜灏忔椂灏卞ソ浜嗐€傛渶鍚庤皟鍏ュ啺绯栨垨鑰呯偧涔炽€?銆佹渶濂借枏绫炽€佽姟瀹炲拰绾㈣眴鎴?Adze?Adze?锛屽皢鑺″疄钖忕背绾㈣眴鎻愬墠娴告场濂姐€?I’m afraid to read it, press it to read it, and read it to paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper, paper.Do you want to click on the button? Do you want to see it? Do you want to go?4 鎻愬墠鏅氫笂鍋氬ソ锛屾棭涓婅捣鏉ュ氨鍋氬畬浜嗐€?銆佽枏绫冲張鍚嶈嫛浠併€佽枏浠併€佽枏绫充粊锛屾槸甯哥敤鐨勪腑鑽紝鍙堟槸鏅亶銆佸父鍚冪殑椋熺墿銆備富瑕佹垚鍒嗕负铔嬬櫧璐ㄣ€佺淮鐢熺礌B1銆丅2 銆?1銆佹湁鍒╂按娑堣偪銆佸仴鑴惧幓婀裤€佽垝绛嬮櫎鐥广€佹竻鐑帓鑴撶瓑鍔熸晥锛屼负甯哥敤鐨勫埄姘存笚Crotchy?2銆佺敤浜庡ご鍙戯細瀹冨叿鏈夎惀鍏诲ご鍙戙€侀槻姝㈣劚鍙戯紝骞朵娇澶村彂鍏夋粦鏌旇蒋鐨勪綔鐢ㄣ€?3 銆 佺 浜 庣 床 寊 寊 寏 圏 間 閊 寊 傊 咜 刊 咊 麴 卑 忓 嚓 瓄 铄 谓 谾 姾 秷 闄 よ 壊 姱 峳 峤 凤凤 凤凤 冤 冤 醲 冲 冮 冤 冤 冤 冤 冤What are you talking about? If you want to know how to do it, you will be able to use it as a guide. If you want to use it, you will be able to use it.濡嗗搧涓繕鍙揪鍒伴槻鏅掑拰闃茬传澶栫嚎鐨勬晥鏋溿€?4 銆 住 栠 佺 珻 鏄?b鐗╃殑涓€绉嶏紝浠ユ按鐓蒋鎴栫倰鐔燂紝姣旇緝鏈夊埄浜庤偁鑳冪殑鍚告敹锛岃韩浣撳父瑙夌柌鍊︽病鍔涙皵鐨勪汉锛屽彲浠ュ鍚冦€傝枏浠佷腑鍚湁涓板瘜鐨勮泲鐧借川鍒嗚В閰电礌锛岃兘浣跨毊鑲よ璐ㄨ蒋鍖栵紝瀵圭毊鑲よ禈鐤c€佺矖绯欎笉鍏夋粦鑰咃紝闀挎湡鏈嶇敤涔熸湁鐤楁晥銆?

[Green peel walnut]_green peel walnut_benefit_prerequisites

銆愰潚鐨牳妗冦€慱闈掔毊鏍告_濂藉_鐩婂
鐜板湪寰堝浜虹粡甯镐細琚墰鐨櫍锛屽ご鐧o紝鐥ょ柈锛岃偂鐧o紝杩欎簺鎵€璋撶殑鐧i兘鏄毊鑲ょ柧鐥咃紝涔熸槸鐪熻弻鎰熸煋閫犳垚鐨勩€傚緢澶氫汉鍦ㄧ敤鍖诲鐨勬不鐤楀悗娌℃湁鐢ㄧ殑锛岄偅涔堣繖涓椂鍊欏ぇ瀹跺彲浠ュ皾璇曚竴涓嬮潚鐨牳妗冦€傞潚鐨牳妗冧腑鍏锋湁娑堥櫎鐪熻弻鎶戝埗鐐庣棁鐨勪綔鐢紝瀵逛簬涓€浜涘ぉ鐒剁殑鍏村鍓傚苟鏈夊府鍔┿€?Proclaimed that there was nothing to say.This is the same as the one in the world. It ‘s very easy to see what is happening in the chain. It ‘s a lot of time. It ‘s a lot of time./旗缁忓崖鐢垫椿锷ㄦ湁鏄捐宪褰卞搷锛涢潚镙告镞犳満鐩愬彲鎻愰珮灏忛紶鑴戝唴K / Ca绂诲瓙姣斿€硷紝浣垮皬榧犺剳鍐?-HT鍚噺澧炲姞锛屽湪涓灑绁炵粡绯荤粺浣滅敤涓嬶紝婵€鍙戞煇浜涚缁忓厓浣夸箣閲婃斁閫掕川绛夎皟鍒朵簡鐥涜鍙嶅簲锛岃揪鍒版鐥涙晥鏋溿€?鍙﹀锛岄矞闈掔毊姹侊紙骞茬毊钂告按锛夊彲娑傛不椤界櫍銆傜敤鍒€鍓婁笅椴滃鏍告缁胯壊澶栫毊澶栫敤鍙不浣撶櫍銆佽偂鐧c€佺墰鐨櫍銆佸ご鐧e強绉冪柈銆傛牳妗冮潚鐨腑鍚湁澶氱鐢熺墿娲绘€ф垚鍒嗭紝鍦ㄥ叾鏈垚鐔熷墠鍚湁澶ч噺缁寸敓绱燙銆傞噰鐢˙SLB锛坆rine shrimp lethelity bioassay锛夋硶瀵规牳妗冮潚鐨彁鍙栫殑娲绘€ф垚鍒嗚繘琛屽垵姝ョ瓫閫夌殑缁撴灉琛ㄦ槑銆?You will be able to pick up a lot of people, and you will be able to catch them, you will be able to pick them up, you will be able to pick them up, and you will be able to pick them up.I ‘m not sure what to do, I ‘m not sure what to do, what to do, what to do, what to do, what to do, what to do, what to do, what to do, what to do, what to do and what to do昏倽鑳冩皵鐥涳紝鑳冪缁忕棝锛屾€ャ€佹參鎬ц儍鐥涖€?0涓栫邯50骞翠唬鍥藉唴澶栨皯闂寸敤闈掓牳妗冩场閰掑墏娌荤枟鑳冪棝銆佺棝缁忋€佺檶鐥囩棝绛夛紝浠ヤ唬鏇垮悧鍟°€侀樋鐗囬厞绛夋鐥涜嵂锛屽凡鏀跺埌浜嗚壇濂界殑姝㈢棝鏁堟灉銆?

[DIY Beef Noodle Practice]_DIY Beef Noodle Practices _DIY Beef Noodle Practices Dad _How to Make DIY Beef Noodles

[DIY Beef Noodle Practice]_DIY Beef Noodle Practice

We in China have a saying that if you want to keep one’s heart, you must first keep his stomach.

I want to see this sentence. Both men and women understand how important it is to make good dishes. Today, I will show you how to make DIY beef noodles, and learn a lot.

The right amount of beef 2.

Shallots and cucumbers are shredded and set aside 3.

Sections three two 4.

Remove the blood foam as soon as possible, then add soy sauce, salt, vegetarian, and spring onion, and press 5 with a pressure cooker.

Put water in the pot and boil.

After the water is boiling, cook the noodles and cook for a while.

7.

Then drain the water.

8.

Pressure cooked beef 9.

Pour the beef and beef soup into the noodles and continue cooking until the noodles are cooked.

Finished DIY beef noodles.

.
.
I put cucumbers. If you love coriander, put some coriander. You can see here. You also fully understand the detailed method of DIY beef noodles.

I hope you can practice as soon as you master the practice.

Only by accelerating your practice can you accelerate the enjoyment of delicious food.

Zhibang Home Furnishing (603801): Wide range of equity incentives, long-term development momentum is sufficient

Zhibang Home Furnishing (603801): Wide range of equity incentives, long-term development momentum is sufficient

Event: The company released the 2020 budget stock incentive extension. It plans to grant stock incentives to 212 middle managers at a grant price of 9.

65 yuan / share, granting a total of 477.

600,000 shares, accounting for about 2 of the company’s equity.

14%.

Opinion: Expand the scope of equity incentives and fully motivate employees.

The company launched the 2019 equity incentive plan in September last year. The target of the award is five executives, and the cumulative amount is 1.29 million shares at a price of 9.

65 yuan / share.

The equity incentive plan has expanded the scope of incentives, with a total of 212 incentive targets as middle management personnel.

The maximum reward is 477.

600,000 shares, accounting for about 2 of the company’s equity.

14%, the grant price is 9.

65 yuan / share.

The stock source is A shares of common stock repurchased from the secondary market.

The performance evaluation standards are based on 2018, and the net profit rate from 2019重庆耍耍网 to 2021 is not less than 12%, 24%, and 40%, respectively.

The equity incentive will fully mobilize the enthusiasm of the company’s middle management, effectively restrain the interests of core shareholders, and help the company’s long-term development.

Benefiting from the improvement of the completed end, the furniture retail side is expected to pick up, optimistic about the continued strength of the bulk business.

The area completed in December 2019 was 3.

2.1 billion cubic meters, an increase of 20 in ten years.

2%, an increase of 18.
.

42 points.

The improvement in the completed end will drive real estate demand back up and promote the rebound in furniture retail sales.

Benefiting from the optimization of the company’s customer structure, the promotion of project management and the introduction of the amoeba business model, the company’s bulk business resumed high growth in 2019, and the company’s bulk business in 2019H1 achieved revenue2.

110,000 yuan, an increase of 24 in ten years.

4%.

As the company continues to develop bulk customers and improve its operating efficiency, we are optimistic that bulk businesses will continue to develop strength in 2020.

Earnings forecast and estimation: EPS are expected to be 1 in 19-21.

44、1.

68, 2.

01 yuan, corresponding to PE is 14X, 12X, 10X.

Give “Buy” rating.

Risk reminder: Real estate sales are less than expected, and cabinet wood category integration is less than expected

Science and Technology Board purchase strategy-Biotech (688177)

Science and Technology Board purchase strategy-Biotech (688177)
This report reads:武汉夜生活网 We recommend that Biotech’s reference estimate range is between 0% -9% quantile, corresponding to a price of 32.71 yuan -33.36 yuan. Abstract: On January 23, 2020, the actual quotation of the quotation of the scientific and technological innovation board company Ruisong Technology fell below the 5% quantile, and the market entered the stage of effective information and low-price gaming among institutions.Considering the market’s downward game after the price is anchored, it is recommended that the price of the Biotite quotes quoted on February 6th be considered at the 9% scale. Taking into account, it is estimated that the inquiry range of Biotech on February 6 will be between 0% and 9%, corresponding to 32.71 yuan -33.36 yuan. Biotech focuses on the development of innovative drugs and biosimilars for the treatment of 北京夜生活网 tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.According to the Frost & Sullivan Report, the scale of Chinese biopharmaceuticals is expected to reach 1 by 2030.The global scale of biosimilars in 2018 was USD 7.2 billion, and it is expected to reach USD 1644 in 2030. The scale of China will increase from 1.6 billion in 2018 to USD 58.9 billion in 2030.The company has not generated revenue for the moment. At present, the company has 1 product approved for marketing. There are 4, 1, and 4 products in Phase I, II, and III clinical research stages, of which 3 are biosimilars and 6Innovative medicine, the company has reserved 11 research projects for tumor immunotherapy, autoimmune disease, cardiovascular disease and so on.In the future, the company will accelerate the process of product industrialization and marketization, realize the listing and sales of a variety of drugs under research, and focus on the research and development of innovative drugs and biosimilars. Based on the market value and product line profile of listed companies, we chose Fuhong Hanlin (2696.HK) is a comparable company. Biotech and Fuhong Hanlin have been approved to be listed on the market and the number of products in Phase II and Phase III clinical research is the same. However, Biotech has only 4 products in Phase I clinical research.Fuhong Hanlin owns five products, and Fuhong Hanlin’s product HLX01 (Han Li Kang) has been commercialized earlier, and is used in clinical quantities.Therefore, based on the market value of Fuhong Hanlin, we give a certain discount to Biotech, based on its estimated total share capital after the issue is not more than 410,080,000 shares. The estimated market size after the issue is 13.5-16.5 billion yuan, corresponding to the issue price range.Is 32.71-39.95 yuan. Risk reminders: (1) The actual quotation center is gradually moving downwards. Be wary of 10% high price rigidity to eliminate risks and the second game behavior on the day of market quotation.(2) The progress of drug development and marketing was less than expected.

Shanghai Pharmaceuticals (601607): State-owned enterprise reform plan landing stock budget incentives to stimulate new vitality

Shanghai Pharmaceuticals (601607): State-owned enterprise reform plan landing stock budget incentives to stimulate new vitality

Event: The company released the stock budget incentive plan for 2019, and plans to reward 28.42 million stock budgets to the incentive objects, accounting for 1 of the company’s share capital.

0%, the exercise price is 21.

54 yuan / share, of which 25.96 million shares were awarded for the first time, accounting for 91 of the total supplementary grants of the plan.

3%, 2.46 million copies of the budget.

The scope of the incentive is wide and strong, and it is expected to fully mobilize the team’s potential: This incentive includes 8 core senior management teams and 207 middle management personnel and core backbones. Among them, the senior management team authorized a total of 2.91 million copies, and the per capita authorization was 36.

40,000 copies, the rest are 11 per capita.

10,000 copies, follow 21.

The authorized price of 54 yuan / share, the total market value of the first authorized share is 5.

600 million, with an average market value of 783 executives.

50,000 yuan, other people per capita ranking 239.

9 million, which is far higher than the average annual salary level per capita, reflecting the wide scope and strength of the latest incentive scheme, which is expected to fully stimulate the enthusiasm of the company’s senior management and core backbone personnel and improve the company’s operating efficiency.

Both the quality and quantity of this incentive plan are considered, and the quality of profit and the evaluation of R & D innovation are the highlights: In this incentive plan, according to the company’s “quality, scale, innovation” as the core strategic guidance, the evaluation indicators take into account performance, profit quality and R & D innovationEtc., 1) Revenue: Based on the average operating income from 2016 to 2018 as the base, the compound revenue from 2020-2022 will not be less than 10.

0%, 10.

0%, 10.

0%, and the revenue scale is not less than 175 billion, 185 billion, 2000 ppm; 2) ROE (deduction): the company’s average average return on net assets in 2020-2022 is not less than 12.

0%, 12.

2%, 12.

4%; 3) R & D end: The company’s R & D investment will not be less than 900 million in 2020-2022,9.

5 billion, 10.

0 ppm; 4) Performance comprehensive index: 2020-2022 will not be lower than the 75th place of the target company.

In terms of subdivisions, in this performance comprehensive index evaluation system, the weighted ratios of return on net assets, industrial income, business income, and R & D expenses are respectively 40%, 30%, 10%, and 20%, which further reflects one time.The improvement of the quality of profit, the improvement of the income structure (more emphasis on the growth of industrial sales), and the improvement of the R & D expenditure will help the company gradually replace the R & D innovative enterprise.

Profit forecast and rating.

We expect EPS to be 1 in 2019-2021.

48 yuan, 1.

66 yuan and 1.

83 yuan, corresponding to the current expected estimates are 15 times, 13 times and 12 times.

As one of the leaders in the domestic pharmaceutical trade field, this vigorous incentive plan is expected to fully 杭州桑拿网 stimulate the leading enthusiasm, which is the basis for the company’s long-term stable growth and growth, with a target price of 26.

6 yuan, the first coverage given a “buy” rating.

Risk warning: product development may be less than expected; drug tendering significantly reduces price risk; and industry competition risks intensifying.

Yunhai Metal (002182) 2019 First Quarterly Report Review: The Company’s Non-Net Profit Deduction Consecutively Increased and Lightweight Layout Assisted Development

Yunhai Metal (002182) 2019 First Quarterly Report Review: The Company’s Non-Net Profit Deduction Consecutively Increased and Lightweight Layout Assisted Development

The company is a leader in the domestic magnesium industry. Its continuous R & D expansion and lightweight downstream layout 北京夜生活网 support the company’s long-term future development.

With reference to the estimated level of the A-share metal smelting and processing entity company, combined with the company’s growth attributes and target scarcity, the company is given 17 times PE in 2019, corresponding to a target price of 12.

1 yuan, maintain “Buy” rating.

In the first quarter of 2019, the company’s non-net profit increased significantly in ten years.

The company achieved revenue of 11 in the first quarter.

90 ppm, a 10-year increase2.

75%, down 7 from the previous month.

78%; net profit attributable to mother is 0.

47 ppm, a reduction of 17 per year.

65%, a decrease of 42.

04%; net profit deducted from non-mother 0.

410,000 yuan, an increase of 195 in ten years.

91%, down 49.

63%.

1) The gross profit margin and the average income increased, compared with the same period last year, the gross profit margin increased from 12.

30% increased to 14.

60%, gross profit from 1.

4.2 billion rose to 1.

74 ppm, an increase of 22 in ten years.

54%, mainly due to rising product prices and lower raw material costs, the price of magnesium ingots rose by approximately 11 in the first quarter of 2019.

42%, the cost of coal / ferrosilicon doping is about 6.

9% / 18.

1%.

2) Demolition compensation budget is the main reason for the decrease in net profit. The company’s other comprehensive income for the same period last year was zero.

930,000 yuan, only 0 in the first quarter of this year.

07 trillion, a year of reduction of 0.

8.6 billion yuan.

The net operating cash flow has increased significantly, and the company’s operations have increased protection.

The company’s cash reserves increased significantly in Q1 2019.

Net cash flow from operating activities increased by 692 annually.

68% to 0.

870,000 yuan, the net cash flow from investment activities increases by 0 every year.

12 trillion, to maintain a balanced cash flow from financing activities.

Net increase in cash and cash equivalents in the first quarter was zero.

90 billion US dollars, the balance of cash and equivalent supplies increased by 109.

79%, ample liquid assets provide the company with more potential investment opportunities in the future.

The lightweight layout opens up and the cost advantage is outstanding.

In the first quarter, the company dated Baosteel Metal, a strategic investor, and is expected to make full use of Baosteel’s scale, channels and customer verification advantages in the automotive industry to achieve rapid development of magnesium alloys in the automotive field.The company is the only vertical tank magnesium smelting company in the industry that uses automation and high production efficiency. The cost per ton of raw magnesium is less than 1,000 yuan in the industry. The cost and R & D strength support the company’s long-term development.

Risk factors: The price of magnesium ingots and magnesium alloys fluctuates, downstream consumption is lower than expected, and project progress is lower than expected.

Investment suggestion: It is 武汉夜网论坛 expected that the company’s net profit attributable to the mother in 2019-2021 will be 4 respectively.

56/5.

49/6.

37 trillion, the corresponding EPS is 0.

71/0.

85/0.

99 yuan.

Considering the absolute and relative estimation methods comprehensively, taking into account the company’s future growth attributes and the scarcity of the target, it is given 17 times PE, and the company’s reasonable target city ranking for 2019 is expected to be 78.

0 billion, corresponding to a target price of 12.

1 yuan, maintain “Buy” rating.

Wanrun Co. (002643): Interim report performance meets expected baseline volume and OLED growth is expected soon

Wanrun Co. (002643): Interim report performance meets expected baseline volume and OLED growth is expected soon

Event description: On August 15, 2019, the company released its semi-annual report for 2019, which stated that the company realized operating income12.

93 ppm, an increase of ten years.

18%; net profit attributable to mother 2.

310,000 yuan, an annual increase of 19.

63%; deduct non-net profit 2.

23 ppm, an increase of 17 in ten years.

37%.

2019Q2 achieved operating income6.

31 ppm, an increase of ten years.

78%, down 4 from the previous month.

7%; net profit attributable to mother 1.

29 ppm, an increase of 0 in ten years.

47%, an increase of 27 from the previous month.

7%.

Incident analysis and description: Cost reduction, product structure optimization and improvement in 2019H1 performance The growth of the company’s 2019H1 net profit growth was mainly due to the decline in raw material prices and product structure optimization, and the company’s cost control was good, thereby increasing the company’s product gross profit margin.

Benefiting from the decline in international oil prices in the first half of 2019, the price of basic chemical raw materials fell, and the company’s gross profit margin for the first half of the year reached 42.

14%, an increase of 5 a year.

09%, the second quarter gross margin reached 45.

1%, a higher level in the company’s history in a single quarter.

The gross profit margins of functional materials and big health business segments increased.

72% and 4.

25%.

In addition, the company’s exchange profit and loss for 2019H1 is -39.

70,000 yuan, down 96 per year.

99%, because the company’s operating income mainly comes from overseas, overseas operating income accounts for more than 80%, the RMB depreciated significantly, which is good for the company’s performance.

2019H1 company operating cash flow2.

99 ppm, a 34-year increase of 34.

5%, the company’s cash flow improved significantly, mainly due to the increase in the report of consolidated sales rebates and the increase in tax refunds received.

The company also further increased its R & D investment to 9870.

70,000 yuan, an annual increase of 23.

6%; R & D expenses 8.

08%, increase by 1 every year.

28%.

Information material segment: The liquid crystal material business is guaranteed, and the growth of OLED materials can be expected in 2019H1. The functional materials segment of the company will achieve operating income10.

400,000 yuan, an increase of 0 in ten years.

2%, gross margin 41.

85%, an increase of 5 per year.

72%.The company is a domestic leader in liquid crystal monomers and intermediates, and is the only domestic supplier of liquid crystal materials to the three giants Merck, Chisso and DIC, with a high market share.

The increase in the volume and area of large-size panels is conducive to increasing the demand for liquid crystal materials. The liquid crystal material business continues to develop toward the growth of downstream demand, so the liquid crystal material business is guaranteed.

At the same time, the company laid out the OLED material industry chain earlier. The subsidiaries Yantai Jiumu Chemical and March Optoelectronics have formed a certain revenue scale and have been recognized by international OLED terminal material factories.

Among them, the subsidiary Jiumu Chemical realized operating income1.

240,000 yuan, net profit attributable to the mother is 21.94 million yuan.

The company’s independent intellectual property rights of OLED finished products have been successfully verified by downstream manufacturers. It is expected to achieve batch supply in 2019.

Since 2018, mainstream mobile phone manufacturers have begun to display foldable mobile phone designs. Samsung and Huawei have successively released foldable mobile phones. The penetration rate of flexible OLEDs will be significantly improved, and curved displays will help promote the significant volume of OLED screens.

The company’s industrial layout of OLED materials fully meets the market potential, and future profits are expected.

Environmental protection material segment: Benefiting from the sixth country, the revenue products have achieved volume development to meet the national six standard emission requirements. The diesel SCR catalyst will be upgraded to a polymer molecular sieve coating, and the polymer molecular 南京夜网 sieve will become the mainstream coating in diesel vehicles.

The company is the core partner of the world’s leading manufacturer of automotive exhaust purification catalysts, and has developed and mass-produced a variety of new solid environmental protection materials for exhaust purification.

The company currently has a total capacity of 3,350 tons / year of copolymer molecular sieve, mainly in the field of high-standard tail gas emissions, and is the core partner of Johnson Matthey.

In addition, “a series of second-stage expansion projects of a series of environmentally friendly materials” is expected to be put into production by the end of the year.

The company plans to use its own funds to invest in projects of 4000 tons / year for the ZB series transformers and 3000 tons / year for the MA series.

With the successive construction and production of a series of environmentally-friendly materials projects, the company will become a high-end series of environmentally-friendly materials producers in the world in terms of technology and sales.

Large health sector: The medical market has huge potential, and the large health industry is expected to rapidly develop the operating income of the large health sector2.

40 ppm, a ten-year increase2.

0%, gross margin 46.

3%, an increase of 4 per year.

25%.

After years of development of the pharmaceutical market and the storage of pharmaceutical technology, the company has been involved in pharmaceutical intermediates, pharmaceutical preparations, bulk drugs, life sciences, in vitro diagnostics and other fields.

In March 2016, the company successfully completed the acquisition of MP, which promoted the effective promotion of the parallel development of the three business segments of the company.

With the economic development, the growth of the world’s population, the serious aging of society, and the change in people’s thinking, per capita medical consumption expenditure has continued to increase in recent years, and the global medical market has continued to grow rapidly with great potential.

In the future, the company will use multiple methods of independent research and development, outsourcing research and development, mergers and acquisitions to rapidly expand the company’s pharmaceutical product line, and achieve rapid development of the large health industry.

Investment Ratings and Estimates We estimate the company’s net profit attributable to its mothers to be 5 in 2019-2021.

34, 6.

47, 7.

9.9 billion yuan, EPS is 0.

59, 0.

71, 0.

88, corresponding PE is 18 respectively.

20, 15.

03, 12.

18. Maintain the “Highly Recommended” rating.

Risks remind that the new project’s commissioning progress is less than expected; the exchange rate changes; raw material prices fluctuate sharply; product prices fluctuate sharply